Spruce Point says IperionX shares ‘significantly overvalued’

Spruce Point Capital, in a research note, said that after conducting a forensic review of IperionX (IPX) and its ambitions of becoming a vertically integrated producer of titanium powders and products, the firm believes that investor expectations are too high, and it faces significant challenges in commercial efforts that may not be fully reflected in its valuation. Spruce Point also expressed concerns with the accuracy of its financial reporting and says it does not believe the end markets to be attractive or that its highly promoted HAMR process is likely to “revolutionize” the industry. Based on the firm’s analysis, Spruce Point advises investors to exercise caution because the shares may be significantly overvalued, with potential downside risk of 70% – 95% under certain scenarios.